<DOC>
	<DOCNO>NCT00240292</DOCNO>
	<brief_summary>The purpose study assess effect rosuvastatin ( up-titrated dose 40mg/day ) compare placebo cardiac remodelling , estimate change leave ventricular ejection fraction radionuclide ventriculography , 26 week post randomisation baseline .</brief_summary>
	<brief_title>Rosuvastatin Impact Ventricular Remodelling Lipids Cytokines</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Signed informed consent , male female age 18 old , LVEF ≤ 40 % assessed RNVG contrast ventriculogram ≤ 35 % assessed TTE within previous 6 month , LVEF &lt; 45 % assessed RNVG Visit 1 , NYHA Class II , III IV symptom primarily relate heart failure , ischaemic nonischaemic patient stable heart failure therapy define physician 's best practice . Key exclusion criterion include acute myocarditis within last 12 month , diabetes mellitus control diet , oral therapy insulin therapy , homozygous familial hypercholesterolaemia , receive biventricular pacing expect receive biventricular pace next 6 month , subject normally would consider statin therapy next 6 month , sever hypertension , history definite myocardial infarction , cerebrovascular accident , percutaneous transluminal coronary angioplasty coronary bypass graft within 3 month prior enrolment study , body mass index &lt; 15 , plus others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Ischaemic non-ischaemic systolic congestive heart failure</keyword>
</DOC>